PharmaTalkRadio

Disruptions in the microbiome are increasingly being linked to an associated risk for serious illnesses, opening up vast potential to create a new category of innovative microbiome-based live biotherapeutics to help people live better lives and advance current standards of care.

 

Today, Dr James Tursi, Chief Scientific Officer of Ferring Pharmaceuticals, discusses study results of Ferring’s Phase III Trial for their microbiome-based live therapeutic (RBX2660), used in the treatment of recurrent C Difficile, and how to harness the potential of the the fast-emerging world of microbiome-based therapeutics.

 

Key takeaways:

Why now is the right time to tackle the microbiomeResults and impact of Ferring's RBX2660 treatmentNext steps for the industry

 

About the speaker:

Dr James Tursi is Chief Scientific Officer, Ferring Pharmaceuticals, responsible for US Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance, Project Planning and Regulatory Affairs. Prior to joining Ferring, as EVP, R&D, Chief Medical Officer for Antares Pharmaceuticals, he created patent extension and portfolio opportunities, was the medical-clinical-PV lead for commercial and business development activities and designed the medical/clinical commercial strategies. Before joining Antares, James held positions of increasing responsibility at Aralez Pharmaceuticals, Auxilium Pharmaceuticals, GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. His therapeutic expertise includes reproductive health, urology, endocrinology (including pediatric), gastroenterology, cardiology, vascular surgery, oncology and neurology.

 

For more information about PharmaTalk Radio, visit theconferenceforum.org.

DPHARM Executive Director, Valerie Bowling gives a 10 minute run down on what you can expect from DPHARM 2021.

Learn more about the conference taking place Septmeber 28-29, 2021 at DPHARMconference.com.

This PharmaTalk Radio episode features Dr Shawn Carbonell, CEO and co-founder of Brazen Bio. 

In this conversation, Dr Carbonell describes how the Brazen Incubator, a turn-key biotech startup incubator, hopes to help fledgling entrepreneurs, the common hurdles that prevent startups from getting off the ground, and recruiting underrepresented founders.

Dr Carbonell started the incubator, based in Los Angeles, with cofounder Dr Brent Witgen.

 

About Dr Carbonell and Brazen: 

In 2009, Dr Carbonell quit neurosurgery residency to found the clinical stage biotech startup, OncoSynergy, Inc, a UCSF spinout. Brazen Bio, which launched in May 2021, is solving the problem Dr Carbonell had over a decade ago when founding his company. Launching a biotech startup requires laboratory access, specialized equipment and other resources. The Brazen Incubator provides the basic infrastructure to founders, including 24/7 laboratory access, resources and housing. 

 

 

For more information about our PharmaTalk podcasts, you can visit theconferenceforum.org. 

For more information about our Chief Medical Officer 360˚ summit, click here; and for more information about our Immuno-Oncology 360˚ conference, click here.

In this conversation between two decentralized clinical trial experts, John Reites, CEO of THREAD, and Andy Iverson, Clinical Outcomes Solutions lead at Medtronic, are discussing decentralized clinical trials: where they don’t work yet and how that might change, the considerations for disease indication and trial type, what technology to use, and what an adoption journey could look like.

 

Key Takeaways:

When DCTs don’t work (yet)

Technology, operations and knowledge perspectives

What a phased approach looks like

Identifying the key stakeholders

 

 

Speakers: 

Andy Iverson is the Clinical Outcomes Solutions lead on the Evidence Optimization Center of Expertise team at Medtronic. In this role he functions as a subject matter expert and project team leader for initiatives related to artificial intelligence, decentralized clinical trials, and interoperability. His career includes 10+ years working with provider and payer systems and data. Andy serves as the Co-Chair of HL7s Biomedical Research and Regulation workgroup and is on the Operations Committee of the HL7 Vulcan FHIR Accelerator. He received a BA in Healthcare Management at Concordia College and an MS in Data Science at Northwestern.

John Reites is CEO of THREAD. Executive intrapreneur turned digital health entrepreneur, his career includes 18 years leading global drug development, clinical trials, decentralized studies and clinical research innovation. As CEO of THREAD, he’s led the company’s efforts to change the way clinical research is conducted, focused on decentralized approaches and enabling the use of their platform to conduct modern research studies while supporting partnerships with their customers.

Learn lessons from a healthcare communications and clinical trial recruitment expert about addressing health disparities in racial and ethnic minorities, utilizing technology to precisely raise awareness, and bridging the digital divide, and how to: 

Leverage technology to raise awareness and engage post-trialChange practices to address mistrust amongst typically underserved populationsUse technology to recruit more diversely and representatively in the pandemic

 

Speaker:

Becky Johnson, PhD, Director, Global Diversity & Inclusion in Clinical Trials, IQVIA: Becky has 20 years of experience in the biopharmaceutical industry and is a subject matter expert in healthcare communications and clinical trial recruitment with a focus on diversity, equity and inclusion. Becky leverages her expertise to inform the strategic direction and initiatives to support pharmaceutical company sponsors with their efforts to achieve more racially and ethnically diverse trial populations. Becky has a Master’s in Public Health and a PhD in Health Sciences. Her doctoral dissertation research focused on facilitating access to clinical trials for racially and ethnically diverse patients. 

 

For more information on PharmaTalk podcasts, click here. 

For more discussions and updates on innovations in clinical trial operations and the use of devices in research, visit theconferenceforum.org to learn about the Patients as Partners in Clinical Research conference.

In this podcast, Roger Boutin, VP of Communications at SCORR Marketing discusses the results of an audience survey from the 2020 CRAACO: Clinical Research as a Care Option Conference. The poll focused on the areas of:

Patient Input and EngagementDealing with COVID and Patient OutreachDiversity and Collaboration Around Clinical TrialsAccelerating the CRAACO Movement

In this conversation, you'll learn lessons of how to implement sensors for the most impact in your clinical trials. Join three sensor experts as they discuss:

What phases of clinical trials are more suited for sensor useHow to select and integrate the deviceHow to ensure compliance

Speaking:

Keith Wenzel, Senior Director, Parexel’s Scientific Data Organization: Keith's areas of subject matter expertise include electronic clinical outcomes assessment, patient sensors and a broad range of eClinical technology used within clinical drug trials.Julia Lakeland, Solutions Architect and Program Director, Parexel: Julia is responsible for selection and implementation of real-world scientific data sources and wearables for clinical trial use. Her background is in product management, operational delivery and support of phase III/IV clinical trials. Thomas Wells, CEO, Precision Digital Health: Thomas is currently focused on bringing innovative big data solutions to market to support real-world evidence research and clinical trial research that scale to meet the shear volume and diversity of data sources with evolution of digital health and precision medicine.

 

For more information on PharmaTalk podcasts, click here. 

For more discussions and updates on innovations in clinical trial operations and the use of devices in research, visit theconferenceforum.org to learn about the upcoming DPHARM: Disruptive Innovations conference, held September 28-29, 2021, and the Mobile in Clinical Trials event, held September 27, 2021.

Patients as Partners Europe conference producer, Mark Scherzer, provides an overview of the upcoming virtual conference agenda to take place 25-26 January 2021. Hear about the sessions, keynotes, interactive opportunities, and what you will walk away with, including:

A range of examples of patient engagement ideas in the early stages of research to advance clinical outcomesAn understanding of how to design hybrid trials around patient preferences to drive better enrollment and retentionHow to increase diversity in clinical trialsHow to manage the issues that arise when implementing new approachesHow to influence organizational change to support patient engagement and clinical research awareness strategiesExpand your professional network by connecting with peers who can provide a wide range of insightsLearn directly from patient advocates who bring a broad spectrum of ideas to the conversations

Learn more about the conference here.

In this podcast, you will hear a panel discussion moderated by Dr Annette Schmid, Takeda Pharmaceuticals from the 2020 IO360° Summit regarding innovations and novel approaches in IO imaging and assessing responses.

Panelists inclue:

Gregory Goldmacher, MD, PhD, MBA, MerckS. Peter Eggleton, MD, FFPM, Merck KGaARon Korn, MD, PhD, Imaging EndpointsMatthew Silva, PhD, Invicro

To learn more about the upcoming 2021 IO360° Summit please visit www.io360summit.com

Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk presented by Dr Lee Albacker, Foundation Medicine and first recorded at the 2020 IO360° Summit, will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response. 

To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com